Prevention of Recurrence of Clostridioides Difficile Colitis with Ursodeoxycholic Acid (UCDA) As a Supplement to Standard Therapy

Launched by MEDICAL COLLEGE OF WISCONSIN · Mar 13, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at whether a medication called Ursodeoxycholic Acid (UDCA) can help prevent the return of Clostridioides difficile (C. diff) colitis, a serious intestinal infection, when used alongside standard antibiotic treatments. Many people who are treated for C. diff experience a recurrence of the infection, so researchers want to see if UDCA can reduce this risk and also lower the need for repeated antibiotic use. The study will involve adults who are diagnosed with C. diff and have certain risk factors for it coming back. Participants will receive standard antibiotic treatment and take UDCA for up to eight weeks.

To be eligible for the study, participants must be at least 18 years old, have a positive test for C. diff, and require standard antibiotic treatment. Those with severe complications or other health issues, such as serious liver disease or who are pregnant, cannot take part. Throughout the trial, participants will be monitored closely for safety and any potential side effects, which may include mild stomach discomfort. This research could potentially lead to new ways to help patients recover from C. diff more effectively and reduce their reliance on antibiotics. The study will take place in Milwaukee, Wisconsin.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Eligible patients: C. diff. toxin +ve patients \> 18 years with one or more risk factors for recurrence \[6,7\] requiring standard treatment with Flagyl, Vancomycin or fidaxomicin.
• Exclusion Criteria:
• • Life expectancy \< 6 months; fulminant colitis; ileus; decompensated liver disease; pregnancy and lactating females; Inability to give informed consent.